SAN ANTONIO (EGMN) - Five years of upfront aromatase inhibitor therapy for early-stage breast cancer is equally effective for the prevention of recurrent disease as a sequential strategy of 2-3 years of tamoxifen followed by an aromatase inhibitor for the balance of the 5 years of adjuvant therapy, according to an updated analysis of the TEAM study.For the primary Tamoxifen Exemestane Adjuvant Multinational (TEAM) end point of disease-free survival 5 years post randomization, the rates were 85.7%...